iSpecimen Inc. (ISPC) is a leading supplier in the burgeoning bio-specimen industry, aiming to advance and accelerate medical research through the ethical procurement and distribution of human biospecimens. Founded in 2009 and headquartered in Lexington, Massachusetts, iSpecimen functions as a key link connecting researchers and scientists with the human specimens they need to drive forward their important work.
iSpecimen's advanced technology platform is instrumental in fueling medical advancements and understanding diseases more comprehensively. Its innovative software platform gives researchers access to millions of high-quality bio-specimens from a broad network of healthcare providers. The specimens are collected from various settings such as hospitals, labs, biobanks and other healthcare organizations.
The company offers a diverse range of specimens - including solid tissues, blood and its derivatives, urine, stool and several others, depending upon the needs of the research. ISPC ensures that each specimen can be annotated with de-identified, HIPAA-compliant clinical data.
A key feature of the iSpecimen's service model is its strict adherence to ethical standards. They ensure that procurement processes are carried out with full patient consent and in compliance with all relevant regulations. This approach not only guarantees respect for donor rights and privacy, but also ensures the legality and ethicality of provided specimens.
iSpecimen has an innovative business model, integrating data analytics with the sourcing of bio-specimens. Its intelligent technology platform leverages existing information in EHRs and other data sources to match the most accurate specimens to a researcher's unique request - expanding the efficiency, speed, and quality of biomarker-based research.
iSpecimen has become an enabler in the field of personalized medicine, cyclically feeding back its research results into the global healthcare system. By facilitating the procurement of biospecimens and linking them to specific digital health records, it accelerates biomarker discovery and validation, speeding up the path to diagnose, treat, and even predict disease.
iSpecimen Inc. fulfills a critical need in today’s research environment, paving the way for major medical breakthroughs by delivering human bio-specimens promptly and ethically. Its contribution to biomedical research makes it an integral part of the healthcare ecosystem aiming to improve patient outcomes. Its corporate philosophy centres around the belief that advances in science are facilitated by advances in the accompanying infrastructure, and the company's work stands testament to this.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
iSpecimen Inc. shares surged by 27.9% in pre-market trading after announcing plans to acquire Foldlab AI assets for $4.5 million, which include AI models, software, and intellectual property. The article also lists other top pre-market movers, including gainers like CEA Industries Inc. and GMEX Robotics Corp., and losers such as Focus Universal Inc. and Dyne Therapeutics, Inc., along with their respective reasons for movement.
iSpecimen Inc. (ISPC) stock is up significantly after the company successfully sourced and shipped hundreds of cancer blood specimens for an international research project within three weeks. This rapid execution highlights the strength of iSpecimen's global network and operational capabilities, serving as a key catalyst for traders despite the company's challenging financial picture and recent stock slide. The news positions ISPC as a speculative trade driven by positive headlines and operational achievements.